Skip To Main Content
Bret David Silverglate on Muck Rack

Bret David Silverglate

As seen in: Taylor & Francis Online
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bret David

Contact Bret David, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The impact of the ketogenic diet on Alzheimer’s disease progression

|
By Zachary R. Grese, Aniketh Naidu, Bret David Silverglate, George T. Grossberg
| Taylor & Francis Online
ABSTRACT Introduction The ketogenic diet as a potential treatment for Alzheimer’s disease (AD) has been investigated in several controlled trials. This topic is significant because of the limited nature of current interventions for AD, and the increasing recognition that lifestyle interventions may be important for reducing the risk of AD. The ketogenic diet is one of the few lifestyle interventions that has the potential to be beneficial after diagnosis.
Open in Who Shared Issue with article?

Profiling lecanemab as a treatment option for Alzheimer’s disease

|
By Emily R. Schiller, Bret David Silverglate, George T. Grossberg
| Taylor & Francis Online
Alzheimer’s disease (AD), a condition common in the elderly, is expected to become more common as the U.S. population ages. Lecanemab is the first fully FDA approved treatment for mild cognitive impairment (MCI) due to AD or mild AD dementia. Other anti-amyloid monoclonal antibodies have reached phase III clinical trials but were withdrawn from clinical development due to ineffectiveness or safety concerns.
Open in Who Shared Issue with article?

Profiling lecanemab as a treatment option for Alzheimer’s disease

|
By Emily R. Schiller, Bret David Silverglate, George T. Grossberg
| Taylor & Francis Online
ABSTRACT Introduction In July 2023, the U.S. Food and Drug Administration (FDA) granted full approval to lecanemab for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD dementia. Considering the limited treatment options for AD, the approval of lecanemab offers hope and opens the door for other disease-modifying therapies in the pipeline.
Open in Who Shared View Duplicates (2) Issue with article?
See all 4 articles